Amniotics
Amniotics is a clinical-stage Swedish biopharmaceutical company developing mesenchymal stem cell (MSC) therapies derived from amniotic fluid, targeting rare diseases including Spinal Muscular Atrophy (SMA). It is pre-revenue, publicly listed on Nasdaq, and operates with a small team.
- Company typePrivate
- Founded2015
- HeadquartersLund, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Amniotics does
Amniotics is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Lund, Sweden, that develops therapeutic candidates based on mesenchymal stem cells (MSCs) isolated from amniotic fluid. The company's core technology platform leverages amniotic fluid as a non-invasive, ethically uncomplicated source of MSCs, which are then manufactured and expanded for potential use in treating serious diseases. Amniotics has positioned its pipeline within the Spinal Muscular Atrophy (SMA) treatment landscape, a rare genetic neuromuscular disorder, joining a competitive field of 18+ companies developing 20+ pipeline therapies for this indication.
The company operates as a publicly listed entity on Nasdaq (ticker: AMNI) with a small team of 1-10 employees led by CEO and founding member Marcus Larsson. Amniotics has secured early-stage funding from Almi Invest (2019) and LU Innovation (2021), reflecting support from regional Nordic investors typical of Swedish biotech ventures at the pre-clinical or early-clinical stage.
The business model is pre-commercial: Amniotics generates no product revenue and operates without distribution channels, pricing, or sales infrastructure. The company funds operations through equity capital and applies resources toward preclinical research, clinical development, regulatory engagement, and scientific publication rather than commercial activities. Any future revenue model would depend on successful clinical advancement, regulatory approval, and the establishment of pharmaceutical distribution or specialty pharmacy partnerships — none of which are currently in place. The company is a sub-scale, capital-constrained participant in a competitive rare disease therapeutic landscape, with reported operating losses declining year over year since a 2021 peak, signaling either disciplined cost management or operational contraction.
Amniotics firmographics
Firmographics- Name
- Amniotics
- Website
- https://amniotics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Amniotics is a clinical-stage Swedish biopharmaceutical company developing mesenchymal stem cell (MSC) therapies derived from amniotic fluid, targeting rare diseases including Spinal Muscular Atrophy (SMA). It is pre-revenue, publicly listed on Nasdaq, and operates with a small team.
- Ownership category
- akta.pro rank
Amniotics industry classification
Industry- Product category
- Cell Therapy / Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)
Keywords
Where Amniotics is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Markets served
Amniotics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Amniotics product offering
Product offeringCore offering
Amniotics is a clinical-stage biopharmaceutical company that develops cell therapies based on mesenchymal stem cells (MSCs) isolated from amniotic fluid. The company is advancing a pipeline of therapeutic candidates, including a program targeting Spinal Muscular Atrophy (SMA), a rare genetic neuromuscular disorder.
Differentiator
Problem solved
Functional benefit
Companies that use Amniotics
Customer profileSegments1 record
Ideal customer profiles1 record
Amniotics technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Amniotics partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights3 records
Amniotics competitors and assessment
Company assessmentDirect peers
- BrainStorm Cell Therapeutics: BrainStorm develops autologous stem cell therapies for neurodegenerative diseases. Comparable to Amniotics as a small clinical-stage cell therapy biotech targeting neurological/neuromuscular indications.
- Athersys: Athersys is a clinical-stage cell therapy company developing MultiStem (an MSC-like platform) for inflammatory, neurological, and pulmonary indications. Direct peer given shared MSC-class platform and clinical-stage profile.
- Mesoblast: Mesoblast is a clinical-stage cell therapy company developing mesenchymal stem cell (MSC)-based therapies for inflammatory and degenerative diseases. It is a direct peer to Amniotics given the shared MSC platform and regenerative-medicine focus.
- Capricor Therapeutics: Capricor develops cell-based therapeutics, including exosome and stem cell-derived therapies, for rare diseases including neuromuscular indications. Comparable to Amniotics in cell-therapy modality and rare-disease focus.
- Scholar Rock: Scholar Rock is a clinical-stage biotech developing therapeutics for SMA and other rare diseases, including myostatin-targeting agents. Directly comparable as a peer SMA-focused clinical-stage company.
- Cytokinetics: Cytokinetics develops muscle biology-targeted therapeutics including for SMA and other neuromuscular disorders. Direct peer given shared SMA indication and clinical-stage rare neuromuscular focus.
Broad incumbents
- Biogen: Biogen commercializes Spinraza, the leading approved SMA therapy. It is a broad incumbent in the same disease space and a key competitive benchmark for any new SMA entrant like Amniotics.
- Novartis: Novartis markets Zolgensma, a one-time gene therapy for SMA. As a broad incumbent in the SMA treatment landscape, Novartis defines the competitive ceiling for new SMA entrants.
Emerging players
- PTC Therapeutics: PTC Therapeutics is a rare-disease focused biopharma with SMA-relevant programs (including risdiplam partnerships) and broader neuromuscular pipeline. Emerging peer given overlapping rare-disease and SMA-adjacent focus.
- Ionis Pharmaceuticals: Ionis pioneered antisense oligonucleotide therapies and is the originator of Spinraza (licensed to Biogen). Comparable as a clinical/RNA-based neuromuscular drug developer with SMA heritage relevant to Amniotics' lead indication.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Amniotics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Amniotics leadership team
Management profileNumber of profiles
Profiles1 record
Amniotics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Amniotics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Amniotics
What does Amniotics do?
Amniotics is a clinical-stage biopharmaceutical company that develops cell therapies based on mesenchymal stem cells (MSCs) isolated from amniotic fluid. The company is advancing a pipeline of therapeutic candidates, including a program targeting Spinal Muscular Atrophy (SMA), a rare genetic neuromuscular disorder.
Is Amniotics a public or private company?
Amniotics is a private company. It is classified as public and is currently operating.
When was Amniotics founded?
Amniotics was founded in 2015. It employs 1 to 10 people.
Where is Amniotics based?
Amniotics is headquartered in Lund, Sweden, in the Europe region.
Who are Amniotics's main competitors?
Direct peers on record are BrainStorm Cell Therapeutics, Athersys, Mesoblast, Capricor Therapeutics, Scholar Rock and Cytokinetics. Broad incumbents are Biogen and Novartis. Emerging players are PTC Therapeutics and Ionis Pharmaceuticals.
Does Amniotics have an API?
No public API is recorded for Amniotics.
What industry is Amniotics in?
Amniotics's product category is Cell Therapy / Biopharmaceuticals. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening). Its NAICS code is 541714 and its SIC code is 8000.